Economic Analysis of Deep Brain Stimulation in Parkinson Disease: Systematic Review of the Literature.

[1]  V. Mok,et al.  Cost-effectiveness of subthalmic nucleus deep brain stimulation for the treatment of advanced Parkinson disease in Hong Kong: a prospective study. , 2014, World neurosurgery.

[2]  T. Simuni,et al.  Cost of deep brain stimulation for the treatment of Parkinson's disease by surgical stimulation sites , 2014, Movement disorders : official journal of the Movement Disorder Society.

[3]  A. Rivero-Santana,et al.  Deep brain stimulation in Parkinson’s disease: meta-analysis of randomized controlled trials , 2014, Journal of Neurology.

[4]  G. Deuschl,et al.  The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson’s disease , 2013, Journal of Neurology.

[5]  Günther Deuschl,et al.  Cost‐effectiveness of deep brain stimulation in patients with Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[6]  Anthony H V Schapira,et al.  Timing of Deep Brain Stimulation in Parkinson Disease: A Need for Reappraisal? , 2013, Annals of neurology.

[7]  David Moher,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[8]  F. Valldeoriola,et al.  Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study , 2013, Journal of medical economics.

[9]  M. Stacy,et al.  The economic and quality of life burden associated with Parkinson's disease: a focus on symptoms. , 2012, The American journal of managed care.

[10]  K. Burchiel,et al.  Randomized trial of deep brain stimulation for Parkinson disease , 2012, Neurology.

[11]  W. Oertel,et al.  Pharmacoeconomic considerations of treating patients with advanced Parkinson's disease , 2012, Expert opinion on pharmacotherapy.

[12]  T. Dóczi,et al.  [Analysis of antiparkinsonian drug reduction after bilateral subthalamic deep brain stimulation]. , 2010, Ideggyogyaszati szemle.

[13]  R. Bittar,et al.  Deep brain stimulation for Parkinson’s disease: Australian referral guidelines , 2009, Journal of Clinical Neuroscience.

[14]  J. Puig-Junoy,et al.  Revisión de la evidencia económica sobre el uso de la estimulación cerebral profunda en la enfermedad de Parkinson avanzada , 2009 .

[15]  Francesc Valldeoriola,et al.  Prospective comparative study on cost‐effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[16]  J. Volkmann,et al.  Deep brain stimulation in late stage Parkinson’s disease: a retrospective cost analysis in Germany , 2005, Journal of Neurology.

[17]  P. Konrad,et al.  Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs. , 2004, Parkinsonism & related disorders.

[18]  M. Cavallo,et al.  Analisi dei costi della stimolazione cerebrale profonda (DBS) nella malattia di Parkinson: uno studio osservazionale su pazienti italiani , 2002 .

[19]  H. Freund,et al.  Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus , 2002, Journal of Neurology.

[20]  R. Holloway,et al.  Deep brain stimulation in the treatment of Parkinson’s disease , 2001, Neurology.

[21]  A. Siderowf,et al.  Cost‐effectiveness analysis in Parkinson's disease: Determining the value of interventions , 2000, Movement disorders : official journal of the Movement Disorder Society.

[22]  W. Oertel,et al.  Cost of illness and its predictors for Parkinson’s disease in Germany , 2012, PharmacoEconomics.

[23]  S. Salek,et al.  A Review of the Health-Related Quality of Life and Economic Impact of Parkinson’s Disease , 2006, Drugs & aging.